Mainstream

Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates

Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates

Post ContentntlaRead More

You might also be interested in reading Ethereum Foundation Picks New Co-Executive Directors, Following Leadership Reshuffle.

August 8, 2025
In Mainstream